Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 4/20 | 0.38 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18252840 | 0.84 | RXRA (0.40) | RXRARXRGTAS2R14KIF11MRGPRX4 | |
| SCHEMBL681508 | 0.83 | IDO1 (0.47) | MRGPRX4TACR1 | |
| SCHEMBL172834 | 0.82 | RXRA (0.46) | RXRARXRGTAS2R14KIF11MRGPRX4 | |
| SCHEMBL21900404 | 0.82 | RXRA (0.39) | RXRARXRGTAS2R14KIF11MRGPRX4 | |
| Hydrochloric Acid SCHEMBL1970955 | 0.81 | IDO1 (0.48) | MRGPRX4TACR1 | |
| SCHEMBL17319636 | 0.80 | RXRA (0.47) | RXRARXRGTAS2R14KIF11MRGPRX4 | |
| SCHEMBL24108532 | 0.79 | RXRA (0.46) | RXRARXRGTAS2R14KIF11MRGPRX4 | |
| SCHEMBL129227 | 0.79 | RXRA (0.49) | RXRARXRGTAS2R14KIF11MRGPRX4 | |
| SCHEMBL2390020 | 0.79 | RXRA (0.49) | RXRARXRGTAS2R14KIF11MRGPRX4 | |
| SCHEMBL130428 | 0.79 | RXRA (0.46) | RXRARXRGTAS2R14KIF11MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CHEMOCENTRYX, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20190269664-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-09-05 | — | — | US | disclosed |
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-11 | — | — | US | disclosed |
| WO-2019136368-A2 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| WO-2019060820-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | LOXL2 568/4885RXRA 474/4885RXRG 496/4885 |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CCR2, CXCR2, CCRL2 | LOXL2 568/4885RXRA 474/4885RXRG 496/4885 |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | LOXL2 1993/4885RXRA 402/4885RXRG 316/4885 |
| US-20190269664-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | LOXL2 629/4885RXRA 499/4885RXRG 505/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | LOXL2 1201/4885RXRA 247/4885RXRG 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.